Synonym
FK 070; FK-070; FK070; KDI 792; KDI792; KDI-792 HCl; KDI-792 hydrochloride
IUPAC/Chemical Name
5-Hexenoic acid, 6-((2S,4R)-4-(((4-chlorophenyl)sulfonyl)amino)-1-(3- pyridinylmethyl)-2-pyrrolidinyl)-, monohydrochloride, (5Z)-
InChi Key
JGCFJVFIRFTRKJ-YOLZMAEBSA-N
InChi Code
InChI=1S/C22H26ClN3O4S.ClH/c23-18-8-10-21(11-9-18)31(29,30)25-19-13-20(6-2-1-3-7-22(27)28)26(16-19)15-17-5-4-12-24-14-17;/h2,4-6,8-12,14,19-20,25H,1,3,7,13,15-16H2,(H,27,28);1H/b6-2-;/t19-,20-;/m1./s1
SMILES Code
Cl.OC(=O)CCC\C=C/[C@@H]1C[C@H](CN1Cc2cccnc2)NS(=O)(=O)c3ccc(Cl)cc3
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
500.43
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1. Sone H, Okuda Y, Tsurushima Y, Asano M, Suzuki S, Kawakami Y, Yamashita K. Acute effects of thromboxane dual blocker (KDI-792) on different portions of lower limb blood flow--a study using Doppler ultrasonography and laser Doppler flowmetry in type 2 diabetic patients. Prostaglandins. 1997 Jun;53(6):395-409. doi: 10.1016/s0090-6980(97)00057-9. PMID: 9261860.
2. Ono Y, Katoh M, Hirayama A, Koike T. Improvement in blood flow and diabetic neuropathy by thromboxane A2 dual blocker KDI-792. Prostaglandins Leukot Essent Fatty Acids. 1995 Aug;53(2):139-45. doi: 10.1016/0952-3278(95)90141-8. PMID: 7480076.
3. Uematsu T, Kosuge K, Umemura K, Nakano M, Terakawa M, Nakashima M. Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers. J Pharm Pharmacol. 1996 Apr;48(4):380-5. doi: 10.1111/j.2042-7158.1996.tb05937.x. PMID: 8794987.
4. Sone H, Okuda Y, Kawakami Y, Yamashita K. Effects of high glucose concentration and a thromboxane synthase inhibitor on the production of thromboxane A2 and prostaglandin I2 and E2 by retinal endothelial cells. Life Sci. 1996;58(3):239-43. doi: 10.1016/0024-3205(95)02281-3. PMID: 9499164.
